No quarterly revenue total was found in CNS Pharmaceuticals, Inc.'s SEC filings.
CNS Pharmaceuticals, Inc. (CNSP) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$3.5 million.
Revenue
—
Net income
$-2.59M
-9.0% vs year-ago quarter
Operating cash flow
$-3.54M
+33.8% vs year-ago quarter
Free cash flow
$-3.54M
+23.9% vs prior quarter
EPS
$-0.38
+94.1% vs year-ago quarter
Dividend per share
None
Shares outstanding
1.46M
+154.4% vs year-ago quarter
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CNSP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Houston, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1729427
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$2.7M | -$5.0M | -$6.0M | -$3.3M | -$2.4M |
| Net income | -$2.6M | -$4.9M | -$6.0M | -$3.2M | -$2.4M |
| Diluted EPS | -$0.38 | -$7.30 | -$9.74 | -$5.76 | -$6.42 |
| Operating cash flow | -$3.5M | -$4.6M | -$3.1M | -$2.2M | -$5.3M |
| Free cash flow | -$3.5M | -$4.7M | — | — | — |
| Total assets | $21.9M | $4.7M | $8.6M | $11.9M | $14.5M |
| Total liabilities | $3.7M | $4.6M | $4.1M | $2.0M | $1.4M |
| Stockholders' equity | $18.2M | $71,000 | $4.5M | $9.9M | $13.1M |
| Cash and investments | $20.0M | $3.0M | $7.2M | $9.9M | $12.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Oct 2, 2026 | Sep 30, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 2, 2026 | Jul 2, 2026 |
| 10-Q | Quarterly report | May 14, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Officer or director change
|
May 4, 2026 | May 4, 2026 |
| 10-K/A | Amended annual report | Apr 30, 2026 | Dec 31, 2025 |
All 390 CNS Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.